Home » Stocks » IMLFF

InMed Pharmaceuticals, Inc. (IMLFF)

Stock Price: $3.45 USD -0.06 (-1.71%)
Updated Oct 22, 2020 12:29 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 18.01M
Revenue (ttm) n/a
Net Income (ttm) -11.28M
Shares Out 5.22M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $3.45
Previous Close $3.51
Change ($) -0.06
Change (%) -1.71%
Day's Open 3.55
Day's Range 3.45 - 3.59
Day's Volume 2,418
52-Week Range 0.1084 - 7.1

More Stats

Market Cap 18.01M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 5.22M
Float 5.16M
EPS (basic) n/a
EPS (diluted) -0.05
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta 2.44
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.04
Revenue n/a
Operating Income n/a
Net Income -11.28M
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share n/a
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -50.41%
ROE -91.74%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$n/a*
*No analysts have provided price targets for this stock.

Financial Performance

Financial Overview

No financial data available for this stock yet.

Company Profile

Company Details

Full Name InMed Pharmaceuticals, Inc.
Country Canada
CEO Eric A. Adams

Stock Information

Ticker Symbol IMLFF
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: IMLFF

Description

InMed Pharmaceuticals, a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, it works on IND-enabling pharmacology and preclinical toxicology studies. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.